Since 2014
Access to pharmaceutical products in six European countries – analysis of different pharmaceutical distribution systems
Farmeconomia
View Archive Info| Field | Value | |
| Title |
Access to pharmaceutical products in six European countries – analysis of different pharmaceutical distribution systems
|
|
| Creator |
Walter, Evelyn
Dragosits, Aline Said, Monira |
|
| Subject |
Pharmacoeconomics; Health economics
Pharmaceutical distribution; Europe; Full-line wholesaler; Direct sales; DTP; RWA |
|
| Description |
OBJECTIVES: The aim of the study was to draw a comprehensive picture of the pharmaceutical wholesale sector, outlining its socio-economic importance compared to different distribution systems such as short-line wholesaling, direct sales from manufacturers, Reduced Wholesale Arrangements (RWA) and Direct to Pharmacy (DTP) arrangements. Its role is considered from an economic, effectiveness and, most importantly, a public health viewpoint with qualitative and quantitative methods, focusing on France, Germany, Italy, the Netherlands, Spain and the UK.METHODS: First, data has been sourced from annual GIRP and IMS-Health statistics; second, a systematic literature research verified the empirical findings; third, an online-questionnaire was directed to pharmacies. Further data have been sourced from a questionnaire, addressing GIRP-full-member associations and wholesale companies (return rate 86%).RESULTS: On a weighted average, pharmaceutical full-line wholesalers in the observed countries alone pre-finance € 10.2 bn over a period of 41 days the entire medicine-market and secure the cash-flow of the social-insurers (Germany: € 2.60 bn for 38 days; Italy: € 2.27 bn for 68 days; the UK: € 1.48 bn for 36 days; France: € 1.28 bn for 22 days; Spain: € 969.76 m for 27 days; the Netherlands: € 399.09 m for 30 days on average). On average, pharmaceutical full-line wholesalers are bundling products of 18.28 manufacturers per delivery. The process costs would increase by € 164,922.43 to € 171,510.06 per year, if there were no pharmaceutical full-line wholesalers. These additional costs would have to be paid by manufacturers, pharmacies and finally by patients. Regarding the satisfaction with different distribution models, the results of the online-questionnaire show that pharmacists in the observed countries are very satisfied with the distribution through their pharmaceutical full-line wholesalers.CONCLUSIONS: The study showed that pharmaceutical full-line wholesalers have an important and unique position in the pharmaceutical supply chain. Special functions like the pre-financing of the entire medicinal product market, or the guarantee of the continuous supply of all medicinal products verify these findings.
|
|
| Publisher |
SEEd Medical Publishers
|
|
| Contributor |
—
|
|
| Date |
2012-03-14
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — |
|
| Format |
text/html
application/pdf |
|
| Identifier |
https://journals.edizioniseed.it/index.php/FE/article/view/192
10.7175/fe.v13i1.192 |
|
| Source |
Farmeconomia. Health economics and therapeutic pathways; Vol 13, No 1 (2012); 33-41
2240-256X |
|
| Language |
eng
|
|
| Relation |
https://journals.edizioniseed.it/index.php/FE/article/view/192/181
https://journals.edizioniseed.it/index.php/FE/article/view/192/188 https://journals.edizioniseed.it/index.php/FE/article/downloadSuppFile/192/21 https://journals.edizioniseed.it/index.php/FE/article/downloadSuppFile/192/22 https://journals.edizioniseed.it/index.php/FE/article/downloadSuppFile/192/23 |
|
| Coverage |
Worldwide
— — |
|
| Rights |
Copyright (c) 2012 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0 |
|